Key result
Patients undergoing heart transplantation for cardiac sarcoidosis had lower 5-year mortality compared to those with non-cardiac sarcoidosis etiologies.
Why the study?
Heart transplantation is a valid option for end-stage heart failure secondary to cardiac sarcoidosis or giant-cell myocarditis, but post-transplantation outcomes in inflammatory cardiomyopathy have been poorly investigated.
Does heart transplantation improve survival in patients with cardiac sarcoidosis or giant-cell myocarditis compared to other heart failure etiologies?
Meta-Analysis (n=162,756)
Does heart transplantation improve survival in patients with cardiac sarcoidosis or giant-cell myocarditis compared to other heart failure etiologies?
Answers are grounded in this paper and cite their sources.
Patients with cardiac sarcoidosis and giant-cell myocarditis have comparable or better post-heart transplantation survival compared to those with other heart failure etiologies, supporting HTx as a valid option for these patients.
Heart transplantation (HTx) is a valid therapeutic option for end-stage heart failure secondary to cardiac sarcoidosis (CS) or giant-cell myocarditis (GCM). However, post-HTx outcomes in patients with inflammatory cardiomyopathy (ICM) have been poorly investigated. We searched PubMed, Scopus, Science Citation Index, EMBASE, and Google Scholar, screened the gray literature, and contacted experts in the field. We included studies comparing post-HTx survival, acute cellular rejection, and disease recurrence in patients with and without ICM. Data were synthesized by a random‐effects meta‐analysis. We screened 11,933 articles, of which 14 were considered eligible. In a pooled analysis, post-HTx survival was higher in CS than non-CS patients after 1 year (risk ratio [RR] 0.88, 95% confidence interval [CI] 0.60–1.17; I2 = 0%) and 5 years (RR 0.72, 95% CI 0.52–0.91; I2 = 0%), but statistically significant only after 5 years. During the first-year post-HTx, the risk of acute cellular rejection was similar for patients with and without CS, but after 5 years, it was lower in those with CS (RR 0.38, 95% CI 0.03–0.72; I2 = 0%). No difference in post-HTx survival was observed between patients with and without GCM after 1 year (RR 1.16, 95% CI 0.05–2.28; I2 = 0%) or 5 years (RR 0.98, 95% CI 0.42–1.54; I2 = 0%). During post-HTx follow-up, recurrence of CS and GCM occurred in 5% and 8% of patients, respectively. Post-HTx outcomes in patients with CS and GCM are comparable with cardiac recipients with other heart failure etiologies. Patients with ICM should not be disqualified from HTx. Graphic abstract
No takes yet. Share an insight, caveat, or question.
Bobbio et al. (2021) conducted a meta-analysis in Cardiac sarcoidosis and giant-cell myocarditis (n=162,756). Cardiac sarcoidosis etiology vs. Non-cardiac sarcoidosis etiologies was evaluated on 5-year mortality post-HTx (RR 0.72, 95% CI 0.52-0.91). Patients undergoing heart transplantation for cardiac sarcoidosis had lower 5-year mortality compared to those with non-cardiac sarcoidosis etiologies.
Synapse has enriched 10 related papers. Consider them for comparative context: